Cholinekinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target

Mohammad Asim; Charles E. Massie; Folake Orafidiya; Nelma Pértega-Gomes; Anne Y. Warren; Mohsen Esmaeili; Luke A. Selth; Heather I. Zecchini; Katarina Luko; Arham Qureshi; Ajoeb Baridi; Suraj Menon; Basetti Madhu; Carlos Escriu; Scott Lyons; Sarah L. Vowler; Vincent R. Zecchini; Greg Shaw; Wiebke Hessenkemper; Roslin Russell; Hisham Mohammed; Niki Stefanos; Andy G. Lynch; Elena Grigorenko; Clive D’Santos; Chris Taylor; Alastair Lamb; Rouchelle Sriranjan; Jiali Yang; Rory Stark; Scott M. Dehm; Paul S. Rennie; Jason S. Carroll; John R. Griffiths; Simon Tavaré; Ian G. Mills; Iain J. McEwan; Aria Baniahmad; Wayne D. Tilley; David E. Neal

doi:10.1093/jnci/djv371

Cholinekinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target

Mohammad Asim, Charles E. Massie, Folake Orafidiya, Nelma Pértega-Gomes, Anne Y. Warren, Mohsen Esmaeili, Luke A. Selth, Heather I. Zecchini, Katarina Luko, Arham Qureshi, Ajoeb Baridi, Suraj Menon, Basetti Madhu, Carlos Escriu, Scott Lyons, Sarah L. Vowler, Vincent R. Zecchini, Greg Shaw, Wiebke Hessenkemper, Roslin RussellHisham Mohammed, Niki Stefanos, Andy G. Lynch, Elena Grigorenko, Clive D’Santos, Chris Taylor, Alastair Lamb, Rouchelle Sriranjan, Jiali Yang, Rory Stark, Scott M. Dehm, Paul S. Rennie, Jason S. Carroll, John R. Griffiths, Simon Tavaré, Ian G. Mills, Iain J. McEwan, Aria Baniahmad, Wayne D. Tilley, David E. Neal

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled the AR-regulated kinome to identify clinically relevant and druggable effectors of AR signaling.
Methods: Using genome-wide approaches, we interrogated all AR regulated kinases. Among these, choline kinase alpha (CHKA) expression was evaluated in benign (n = 195), prostatic intraepithelial neoplasia (PIN) (n = 153) and prostate cancer (PCa) lesions (n = 359). We interrogated how CHKA regulates AR signaling using biochemical assays and investigated androgen regulation of CHKA expression in men with PCa, both untreated (n = 20) and treated with an androgen biosynthesis inhibitor degarelix (n = 27). We studied the effect of CHKA inhibition on the PCa transcriptome using RNA sequencing and tested the effect of CHKA inhibition on cell growth, clonogenic survival and invasion. Tumor xenografts (n = 6 per group) were generated in mice using genetically engineered prostate cancer cells with inducible CHKA knockdown. Data were analyzed with χ 2 tests, Cox regression analysis, and Kaplan-Meier methods. All statistical tests were two-sided.
Results: CHKA expression was shown to be androgen regulated in cell lines, xenografts, and human tissue (log fold change from 6.75 to 6.59, P = .002) and was positively associated with tumor stage. CHKA binds directly to the ligand-binding domain (LBD) of AR, enhancing its stability. As such, CHKA is the first kinase identified as an AR chaperone. Inhibition of CHKA repressed the AR transcriptional program including pathways enriched for regulation of protein folding, decreased AR protein levels, and inhibited the growth of PCa cell lines, human PCa explants, and tumor xenografts.
Conclusions:CHKA can act as an AR chaperone, providing, to our knowledge, the first evidence for kinases as molecular chaperones, making CHKA both a marker of tumor progression and a potential therapeutic target for PCa.

Original language	English
Article number	djv371
Journal	Journal of the National Cancer Institute
Volume	108
Issue number	5
Early online date	11 Dec 2015
DOIs	https://doi.org/10.1093/jnci/djv371
Publication status	Published - 1 May 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/djv371Licence: CC BY

Lynch_2016_JNCI_CholineKinaseAlpha_CC
© The Author 2015. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 13.9 MBLicence: CC BY

Cite this

Asim, M., Massie, C. E., Orafidiya, F., Pértega-Gomes, N., Warren, A. Y., Esmaeili, M., Selth, L. A., Zecchini, H. I., Luko, K., Qureshi, A., Baridi, A., Menon, S., Madhu, B., Escriu, C., Lyons, S., Vowler, S. L., Zecchini, V. R., Shaw, G., Hessenkemper, W., ... Neal, D. E. (2016). Cholinekinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target. Journal of the National Cancer Institute, 108(5), Article djv371. https://doi.org/10.1093/jnci/djv371

@article{29db11e3894c4416b7637acd1dedad05,

title = "Cholinekinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target",

abstract = "Background: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled the AR-regulated kinome to identify clinically relevant and druggable effectors of AR signaling. Methods: Using genome-wide approaches, we interrogated all AR regulated kinases. Among these, choline kinase alpha (CHKA) expression was evaluated in benign (n = 195), prostatic intraepithelial neoplasia (PIN) (n = 153) and prostate cancer (PCa) lesions (n = 359). We interrogated how CHKA regulates AR signaling using biochemical assays and investigated androgen regulation of CHKA expression in men with PCa, both untreated (n = 20) and treated with an androgen biosynthesis inhibitor degarelix (n = 27). We studied the effect of CHKA inhibition on the PCa transcriptome using RNA sequencing and tested the effect of CHKA inhibition on cell growth, clonogenic survival and invasion. Tumor xenografts (n = 6 per group) were generated in mice using genetically engineered prostate cancer cells with inducible CHKA knockdown. Data were analyzed with χ 2 tests, Cox regression analysis, and Kaplan-Meier methods. All statistical tests were two-sided. Results: CHKA expression was shown to be androgen regulated in cell lines, xenografts, and human tissue (log fold change from 6.75 to 6.59, P = .002) and was positively associated with tumor stage. CHKA binds directly to the ligand-binding domain (LBD) of AR, enhancing its stability. As such, CHKA is the first kinase identified as an AR chaperone. Inhibition of CHKA repressed the AR transcriptional program including pathways enriched for regulation of protein folding, decreased AR protein levels, and inhibited the growth of PCa cell lines, human PCa explants, and tumor xenografts. Conclusions:CHKA can act as an AR chaperone, providing, to our knowledge, the first evidence for kinases as molecular chaperones, making CHKA both a marker of tumor progression and a potential therapeutic target for PCa.",

author = "Mohammad Asim and Massie, {Charles E.} and Folake Orafidiya and Nelma P{\'e}rtega-Gomes and Warren, {Anne Y.} and Mohsen Esmaeili and Selth, {Luke A.} and Zecchini, {Heather I.} and Katarina Luko and Arham Qureshi and Ajoeb Baridi and Suraj Menon and Basetti Madhu and Carlos Escriu and Scott Lyons and Vowler, {Sarah L.} and Zecchini, {Vincent R.} and Greg Shaw and Wiebke Hessenkemper and Roslin Russell and Hisham Mohammed and Niki Stefanos and Lynch, {Andy G.} and Elena Grigorenko and Clive D{\textquoteright}Santos and Chris Taylor and Alastair Lamb and Rouchelle Sriranjan and Jiali Yang and Rory Stark and Dehm, {Scott M.} and Rennie, {Paul S.} and Carroll, {Jason S.} and Griffiths, {John R.} and Simon Tavar{\'e} and Mills, {Ian G.} and McEwan, {Iain J.} and Aria Baniahmad and Tilley, {Wayne D.} and Neal, {David E.}",

note = "The RNA-seq data generated during this work has been submitted to Gene Expression Omnibus and is available for viewing at the following link http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token = ytazouoixxedjal&acc=GSE63700. ",

year = "2016",

month = may,

day = "1",

doi = "10.1093/jnci/djv371",

language = "English",

volume = "108",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "5",

}

Asim, M, Massie, CE, Orafidiya, F, Pértega-Gomes, N, Warren, AY, Esmaeili, M, Selth, LA, Zecchini, HI, Luko, K, Qureshi, A, Baridi, A, Menon, S, Madhu, B, Escriu, C, Lyons, S, Vowler, SL, Zecchini, VR, Shaw, G, Hessenkemper, W, Russell, R, Mohammed, H, Stefanos, N, Lynch, AG, Grigorenko, E, D’Santos, C, Taylor, C, Lamb, A, Sriranjan, R, Yang, J, Stark, R, Dehm, SM, Rennie, PS, Carroll, JS, Griffiths, JR, Tavaré, S, Mills, IG, McEwan, IJ, Baniahmad, A, Tilley, WD & Neal, DE 2016, 'Cholinekinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target', Journal of the National Cancer Institute, vol. 108, no. 5, djv371. https://doi.org/10.1093/jnci/djv371

TY - JOUR

T1 - Cholinekinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target

AU - Asim, Mohammad

AU - Massie, Charles E.

AU - Orafidiya, Folake

AU - Pértega-Gomes, Nelma

AU - Warren, Anne Y.

AU - Esmaeili, Mohsen

AU - Selth, Luke A.

AU - Zecchini, Heather I.

AU - Luko, Katarina

AU - Qureshi, Arham

AU - Baridi, Ajoeb

AU - Menon, Suraj

AU - Madhu, Basetti

AU - Escriu, Carlos

AU - Lyons, Scott

AU - Vowler, Sarah L.

AU - Zecchini, Vincent R.

AU - Shaw, Greg

AU - Hessenkemper, Wiebke

AU - Russell, Roslin

AU - Mohammed, Hisham

AU - Stefanos, Niki

AU - Lynch, Andy G.

AU - Grigorenko, Elena

AU - D’Santos, Clive

AU - Taylor, Chris

AU - Lamb, Alastair

AU - Sriranjan, Rouchelle

AU - Yang, Jiali

AU - Stark, Rory

AU - Dehm, Scott M.

AU - Rennie, Paul S.

AU - Carroll, Jason S.

AU - Griffiths, John R.

AU - Tavaré, Simon

AU - Mills, Ian G.

AU - McEwan, Iain J.

AU - Baniahmad, Aria

AU - Tilley, Wayne D.

AU - Neal, David E.

N1 - The RNA-seq data generated during this work has been submitted to Gene Expression Omnibus and is available for viewing at the following link http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token = ytazouoixxedjal&acc=GSE63700.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled the AR-regulated kinome to identify clinically relevant and druggable effectors of AR signaling. Methods: Using genome-wide approaches, we interrogated all AR regulated kinases. Among these, choline kinase alpha (CHKA) expression was evaluated in benign (n = 195), prostatic intraepithelial neoplasia (PIN) (n = 153) and prostate cancer (PCa) lesions (n = 359). We interrogated how CHKA regulates AR signaling using biochemical assays and investigated androgen regulation of CHKA expression in men with PCa, both untreated (n = 20) and treated with an androgen biosynthesis inhibitor degarelix (n = 27). We studied the effect of CHKA inhibition on the PCa transcriptome using RNA sequencing and tested the effect of CHKA inhibition on cell growth, clonogenic survival and invasion. Tumor xenografts (n = 6 per group) were generated in mice using genetically engineered prostate cancer cells with inducible CHKA knockdown. Data were analyzed with χ 2 tests, Cox regression analysis, and Kaplan-Meier methods. All statistical tests were two-sided. Results: CHKA expression was shown to be androgen regulated in cell lines, xenografts, and human tissue (log fold change from 6.75 to 6.59, P = .002) and was positively associated with tumor stage. CHKA binds directly to the ligand-binding domain (LBD) of AR, enhancing its stability. As such, CHKA is the first kinase identified as an AR chaperone. Inhibition of CHKA repressed the AR transcriptional program including pathways enriched for regulation of protein folding, decreased AR protein levels, and inhibited the growth of PCa cell lines, human PCa explants, and tumor xenografts. Conclusions:CHKA can act as an AR chaperone, providing, to our knowledge, the first evidence for kinases as molecular chaperones, making CHKA both a marker of tumor progression and a potential therapeutic target for PCa.

AB - Background: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled the AR-regulated kinome to identify clinically relevant and druggable effectors of AR signaling. Methods: Using genome-wide approaches, we interrogated all AR regulated kinases. Among these, choline kinase alpha (CHKA) expression was evaluated in benign (n = 195), prostatic intraepithelial neoplasia (PIN) (n = 153) and prostate cancer (PCa) lesions (n = 359). We interrogated how CHKA regulates AR signaling using biochemical assays and investigated androgen regulation of CHKA expression in men with PCa, both untreated (n = 20) and treated with an androgen biosynthesis inhibitor degarelix (n = 27). We studied the effect of CHKA inhibition on the PCa transcriptome using RNA sequencing and tested the effect of CHKA inhibition on cell growth, clonogenic survival and invasion. Tumor xenografts (n = 6 per group) were generated in mice using genetically engineered prostate cancer cells with inducible CHKA knockdown. Data were analyzed with χ 2 tests, Cox regression analysis, and Kaplan-Meier methods. All statistical tests were two-sided. Results: CHKA expression was shown to be androgen regulated in cell lines, xenografts, and human tissue (log fold change from 6.75 to 6.59, P = .002) and was positively associated with tumor stage. CHKA binds directly to the ligand-binding domain (LBD) of AR, enhancing its stability. As such, CHKA is the first kinase identified as an AR chaperone. Inhibition of CHKA repressed the AR transcriptional program including pathways enriched for regulation of protein folding, decreased AR protein levels, and inhibited the growth of PCa cell lines, human PCa explants, and tumor xenografts. Conclusions:CHKA can act as an AR chaperone, providing, to our knowledge, the first evidence for kinases as molecular chaperones, making CHKA both a marker of tumor progression and a potential therapeutic target for PCa.

UR - https://academic.oup.com/jnci/article/2412425/Choline-Kinase-Alpha-as-an-Androgen-Receptor#supplementary-data

U2 - 10.1093/jnci/djv371

DO - 10.1093/jnci/djv371

M3 - Article

SN - 0027-8874

VL - 108

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 5

M1 - djv371

ER -

Cholinekinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Andy Lynch